HCP
INDV icon

Hexagon Capital Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Hexagon Capital Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12
Closed -$114 – 862
2025
Q1 		$114 Buy
+12
New +$126 ﹤0.01% 1798

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hexagon Capital Partners's INDV Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Indivior Pharmaceuticals (INDV) in Q2 2025, closing a stake of 12 shares — an estimated $114 sold.

Hexagon Capital Partners first reported a position in INDV in Q1 2025 and held it in 1 quarter. The position peaked at $114 in Q1 2025. 120 funds tracked by Wall St. Rank hold INDV as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Indivior Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 12 Indivior Pharmaceuticals shares in Q2 2025, an estimated $114.
  • Hexagon Capital Partners first reported a position in Indivior Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Hexagon Capital Partners's Indivior Pharmaceuticals position peaked at $114 in Q1 2025.
  • 120 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.